Mayne Pharma GroupMAYNF 52 Return-on-Tangible-Asset is -6.66% as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 118 Medical Distribution companies, Mayne Pharma Group ranks worse than 90.68% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mayne Pharma Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $-19.9 Mil. Mayne Pharma Group's average total tangible assets for the quarter that ended in Dec. 2025 was $297.9 Mil. Therefore, Mayne Pharma Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -6.66%.
The historical rank and industry rank for Mayne Pharma Group's Return-on-Tangible-Asset or its related term are showing as below:
MAYNF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -34.79 Med: -18.2 Max: 15.73
Current: -17.14
During the past 13 years, Mayne Pharma Group's highest Return-on-Tangible-Asset was 15.73%. The lowest was -34.79%. And the median was -18.20%.
MAYNF's Return-on-Tangible-Asset is ranked worse than 90.68% of 118
companies
in the Medical Distribution industry
Industry Median: 2.305
vs MAYNF: -17.14
Mayne Pharma Group (OTCPK:MAYNF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Mayne Pharma Group Return-on-Tangible-Asset Related Terms
Mayne Pharma Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAYNF vs MCK, CAH, COR: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -6.66% mean?
Mayne Pharma Group (MAYNF) has a Return-on-Tangible-Asset of -6.66% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #107 out of 118 companies in the Medical Distribution industry, placing it in the top 90.7%.
Is Mayne Pharma Group's Return-on-Tangible-Asset too high?
Mayne Pharma Group's current Return-on-Tangible-Asset is -6.66%. Based on the distribution chart, Mayne Pharma Group ranks #107 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Return-on-Tangible-Asset compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #107 out of 118 companies for Return-on-Tangible-Asset. This places Mayne Pharma Group in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.31, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Return-on-Tangible-Asset is -6.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.97 — trading 46.7% below its estimated fair value. The current Return-on-Tangible-Asset is -6.66%. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Return-on-Tangible-Asset is -6.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.97 is trading 46.7% below its estimated GF Value™ of $3.70.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Return-on-Tangible-Asset: -6.66%
GF Value™: $3.70 vs. price of $1.97 (46.7% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score
Get the complete analysis for MAYNF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
